The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer

Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells

(2014) S. Matsumura et al.   JOURNAL OF IMMUNOLOGY

Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant

(2014) S. Adams et al.   JOURNAL OF IMMUNOLOGY

Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift

(2013) Silvia C. Formenti et al.   JNCI-Journal of the National Cancer Institute

Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer

(2012) S. Adams et al.   CLINICAL CANCER RESEARCH

Synergy of Topical Toll-like Receptor 7 Agonist with Radiation and Low-Dose Cyclophosphamide in a Mouse Model of Cutaneous Breast Cancer

(2012) M. Z. Dewan et al.   CLINICAL CANCER RESEARCH

Suppressing T cell motility induced by anti–CTLA-4 monotherapy improves antitumor effects

(2012) Maria Grazia Ruocco et al.   JOURNAL OF CLINICAL INVESTIGATION

Treatment Failure of a TLR-7 Agonist Occurs Due to Self-Regulation of Acute Inflammation and Can Be Overcome by IL-10 Blockade

(2010) H. Lu et al.   JOURNAL OF IMMUNOLOGY

Toll-like receptor agonists in cancer therapy

(2009) Sylvia Adams   Immunotherapy